全文获取类型
收费全文 | 10753篇 |
免费 | 1114篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 133篇 |
儿科学 | 434篇 |
妇产科学 | 292篇 |
基础医学 | 1584篇 |
口腔科学 | 219篇 |
临床医学 | 1074篇 |
内科学 | 1870篇 |
皮肤病学 | 124篇 |
神经病学 | 1223篇 |
特种医学 | 473篇 |
外科学 | 1368篇 |
综合类 | 312篇 |
一般理论 | 29篇 |
预防医学 | 1010篇 |
眼科学 | 221篇 |
药学 | 827篇 |
中国医学 | 4篇 |
肿瘤学 | 683篇 |
出版年
2020年 | 93篇 |
2019年 | 123篇 |
2018年 | 137篇 |
2017年 | 142篇 |
2016年 | 118篇 |
2015年 | 149篇 |
2014年 | 216篇 |
2013年 | 328篇 |
2012年 | 406篇 |
2011年 | 410篇 |
2010年 | 244篇 |
2009年 | 213篇 |
2008年 | 410篇 |
2007年 | 431篇 |
2006年 | 431篇 |
2005年 | 416篇 |
2004年 | 433篇 |
2003年 | 405篇 |
2002年 | 440篇 |
2001年 | 394篇 |
2000年 | 389篇 |
1999年 | 329篇 |
1998年 | 133篇 |
1997年 | 111篇 |
1996年 | 134篇 |
1995年 | 113篇 |
1994年 | 114篇 |
1993年 | 133篇 |
1992年 | 294篇 |
1991年 | 302篇 |
1990年 | 285篇 |
1989年 | 286篇 |
1988年 | 243篇 |
1987年 | 265篇 |
1986年 | 244篇 |
1985年 | 221篇 |
1984年 | 184篇 |
1983年 | 198篇 |
1982年 | 115篇 |
1981年 | 96篇 |
1979年 | 179篇 |
1978年 | 122篇 |
1977年 | 90篇 |
1976年 | 104篇 |
1975年 | 81篇 |
1974年 | 92篇 |
1973年 | 85篇 |
1972年 | 95篇 |
1971年 | 86篇 |
1968年 | 82篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Jack Cuzick Rachael Adcock Walter Kinney Philip E. Castle Michael Robertson Ruth M. McDonald Mark H. Stoler Ruofei Du Cosette M. Wheeler for the New Mexico HPV Pap Registry Steering Committee 《International journal of cancer. Journal international du cancer》2023,153(1):83-93
Human papillomavirus (HPV) testing for cervical screening increases diagnosis of precancer and reduces the incidence of cervical cancer more than cytology alone. However, real-world evidence from diverse practice settings is lacking for the United States (U.S.) to support clinician adoption of primary HPV screening. Using a population-based registry, which captures all cervical cytology (with or without HPV testing) and all cervical biopsies, we conducted a real-world evidence study of screening in women aged 30 to 64 years across the entire state of New Mexico. Negative cytology was used to distinguish cotests from reflex HPV tests. A total of 264 198 cervical screening tests (with exclusions based on clinical history) were recorded as the first screening test between 2014 and 2017. Diagnoses of cervical intraepithelial neoplasia grades 2 or 3 or greater (CIN2+, CIN3+) from 2014 to 2019 were the main outcomes. Of cytology-negative screens, 165 595 (67.1%) were cotests and 4.8% of these led to biopsy within 2 years vs 3.2% in the cytology-only group. Among cytology-negative, HPV tested women, 347 of 398 (87.2%) CIN2+ cases were diagnosed in HPV-positive women, as were 147 of 164 (89.6%) CIN3+ cases. Only 29/921 (3.2%) CIN3+ and 67/1964 (3.4%) CIN2+ cases were diagnosed in HPV-negative, cytology-positive women with biopsies. Under U.S. opportunistic screening, across a diversity of health care delivery practices, and in a population suffering multiple disparities, we show adding HPV testing to cytology substantially increased the yield of CIN2+ and CIN3+. CIN3+ was rarely diagnosed in HPV-negative women with abnormal cytology, supporting U.S. primary HPV-only screening. 相似文献
2.
Clare Robertson Jan E. Clarkson Magaly Aceves-Martins Craig R. Ramsay Derek Richards Thibault Colloc 《International dental journal》2022,72(2):203-210
IntroductionThe coronavirus disease 2019 (COVID-19) led to the worldwide closure of dental practices or reduction of dental services. By the end of April 2020, governments and professional organisations were publishing recommendations or guidance for the reopening/restructuring of dental services. The aim of this study was to assess how dental aerosol-generating procedures (AGPs) were defined in international dental guidelines, what mitigation processes were advised, and whether they were linked to COVID-19 epidemiology.MethodsElectronic searches of a broad range of databases, along with grey literature searches, without language restriction were conducted up to 13 July 2020. Recommendations for the use of face masks and fallow times with patients without COVID-19 were assessed against the deaths per 1 million population in the included countries and country income level using Pearson Chi-squared statistics.ResultsSixty-three guidance documents were included. Most (98%) indicated that AGPs can be performed with patients without COVID-19 with caveats, including advice to restrict AGPs where possible, with 21% only recommending AGPs for dental emergencies. Face masks were recommended by most documents (94%), with 91% also specifying the use of goggles or face shields. Fallow periods for patients without COVID-19 were mentioned in 48% of documents, ranging from 2 to 180 minutes. There were no significant differences in recommendations for face masks or fallow time in patients without COVID-19 by country death rate (P = .463 and P = .901) or World Bank status (P = .504 and P = .835). Most documents recommended procedural or environmental mitigations such as preprocedural mouthwash (82%) and general ventilation (52%). Few documents provided underpinning evidence for their recommendations.ConclusionsWhile the amount of high-quality direct evidence related to dentistry and COVID-19 remains limited, it is important to be explicit about the considered judgements for recommendations as well as generate new evidence to face this challenge. 相似文献
3.
Lawrence Serfaty Ira Jacobson Jürgen Rockstroh Frederick L. Altice Peggy Hwang Eliav Barr Michael Robertson Barbara Haber 《Journal of viral hepatitis》2019,26(3):329-336
European treatment guidelines for hepatitis C virus (HCV) infection recommend that people with genotype (GT) 1a infection and baseline viral load ≤800 000 IU/mL receive elbasvir/grazoprevir (EBR/GZR) for 12 weeks, and those with baseline viral load >800 000 IU/mL receive EBR/GZR plus ribavirin for 16 weeks. This analysis was conducted to clarify whether baseline viral load can serve as an accurate, sensitive or specific stratification factor for defining EBR/GZR regimens. In this post hoc, integrated analysis, participants with GT1a infection who received EBR 50 mg/GZR 100 mg for 12 weeks were stratified according to baseline viral load. Sustained virologic response at 12 weeks post‐treatment was achieved by 95.2% (911/957) of participants and was higher among participants with baseline viral load ≤800 000 IU/mL vs >800 000 IU/mL (98.5% vs 93.9%). The 800 000 IU/mL threshold had a positive predictive value of 98.5%, a negative predictive value of 6.1%, a specificity of 91.3%, a sensitivity of 28.4% and an overall accuracy of 31.5%. A baseline viral load cutpoint of 800 000 IU/mL had high positive predictive value and specificity but poor negative predictive value, sensitivity and accuracy in predicting treatment outcomes in this population. Baseline NS5A resistance‐associated substitutions (RASs) were detected in 25% (1/4) of virologic failures with baseline viral load ≤800 000 IU/mL and 59.5% (25/42) of those with baseline viral load >800 000 IU/mL. Overall, these data suggest that, compared with the use of a baseline viral load cutpoint, baseline testing for NS5A RASs enables more individuals to receive the 12‐week EBR/GZR regimen without compromising the opportunity for SVR. 相似文献
4.
5.
6.
7.
Elizabeth L. Barry Jennifer L. Lund Daniel Westreich Leila A. Mott Dennis J. Ahnen Gerald J. Beck Roberd M. Bostick Robert S. Bresalier Carol A. Burke Timothy R. Church Judy R Rees Douglas J. Robertson John A. Baron 《International journal of cancer. Journal international du cancer》2019,144(3):448-458
Calcium supplementation (1,200 mg/day) did not significantly reduce colorectal adenomas in our recent randomized, controlled trial (Vitamin D/Calcium Polyp Prevention Study, VCPPS, 2004–2013) in contrast to our previous trial (Calcium Polyp Prevention Study, CPPS, 1988–1996). To reconcile these findings, we identified participant characteristics that differed between the study populations and modified the effect of calcium supplementation on adenomas or high-risk findings (advanced or multiple adenomas). Compared to the CPPS, more participants in the VCPPS were obese (body mass index (BMI) ≥30 kg/m2; 37.5% vs. 24.4%) and fewer had normal BMI (BMI <25 kg/m2; 18.5% vs. 31%). BMI appeared to modify the effect of calcium supplementation on adenomas and especially on high risk-findings: in the VCPPS, there was a 44% reduction in high-risk findings among individuals whose BMI was normal (RR = 0.56, 95% CI = 0.26–1.23), but not among overweight (RR = 1.09, 95% CI = 0.62–1.91) or obese (RR = 1.54, 95% CI = 0.92–2.57) individuals (pinteraction = 0.03). Similarly, in the CPPS, there was a 56% reduction in high-risk findings among individuals whose BMI was normal (RR = 0.44, 95% CI = 0.26–0.74), but not among overweight (RR = 0.87, 95% CI = 0.55–1.39) or obese (RR = 1.02, 95% CI = 0.57–1.82) individuals (pinteraction = 0.02). Standardization of each trial's findings to the BMI distribution in the other attenuated calcium's protective effect on adenomas in the CPPS but enhanced it in the VCPPS. In conclusion, 1,200 mg/day calcium supplementation may reduce risk of colorectal adenomas among those with normal BMI but not in overweight or obese individuals; and differences in BMI distribution partially account for the apparent difference in calcium efficacy between the two trials. 相似文献
8.
Saylor Deanna Nakigozi Gertrude Pardo Carlos A. Kisakye Alice Kumar Anupama Nakasujja Noeline Robertson Kevin R. Gray Ronald H. Wawer Maria J. Sacktor Ned 《Journal of neurovirology》2019,25(3):410-414
Journal of NeuroVirology - We investigated whether vitamin D is associated with HIV-associated neurocognitive disorder (HAND). HIV-infected (HIV+) antiretroviral therapy (ART)-naïve adults in... 相似文献
9.
Kendall J. Burdick Joy D. Cogan Lynette C. Rives Amy K. Robertson Mary E. Koziura Elly Brokamp Laura Duncan Vickie Hannig Jean Pfotenhauer Rena Vanzo Michael S. Paul Anna Bican Thomas Morgan Jessica Duis John H. Newman Rizwan Hamid John A. Phillips III Undiagnosed Diseases Network 《American journal of medical genetics. Part A》2020,182(6):1400-1406
While exome sequencing (ES) is commonly the final diagnostic step in clinical genetics, it may miss diagnoses. To clarify the limitations of ES, we investigated the diagnostic yield of genetic tests beyond ES in our Undiagnosed Diseases Network (UDN) participants. We reviewed the yield of additional genetic testing including genome sequencing (GS), copy number variant (CNV), noncoding variant (NCV), repeat expansion (RE), or methylation testing in UDN cases with nondiagnostic ES results. Overall, 36/54 (67%) of total diagnoses were based on clinical findings and coding variants found by ES and 3/54 (6%) were based on clinical findings only. The remaining 15/54 (28%) required testing beyond ES. Of these, 7/15 (47%) had NCV, 6/15 (40%) CNV, and 2/15 (13%) had a RE or a DNA methylation disorder. Thus 18/54 (33%) of diagnoses were not solved exclusively by ES. Several methods were needed to detect and/or confirm the functional effects of the variants missed by ES, and in some cases by GS. These results indicate that tests to detect elusive variants should be considered after nondiagnostic preliminary steps. Further studies are needed to determine the cost‐effectiveness of tests beyond ES that provide diagnoses and insights to possible treatment. 相似文献
10.
Grant Rebecca K. Brindle William M. Robertson Alexander R. Kalla Rahul Plevris John N. 《Digestive diseases and sciences》2022,67(6):1937-1947
Digestive Diseases and Sciences - Diagnostic unsedated transnasal endoscopy (uTNE) has been proven to be a safe and well-tolerated procedure. Although its utilization in the United Kingdom... 相似文献